



FOR IMMEDIATE RELEASE

Xantos Biomedicine Acquires the OriGene TrueClone™ Collection for HTP Screening

Rockville, MD. August 9, 2004 – OriGene Technologies Inc. today announced Xantos Biomedicine in Germany has acquired access to their TrueClone™ Collection of non-redundant full-length human cDNA clones. Xantos uses its proprietary High-Throughput Cellular Screening Technology, XantoScreen™ and the full-length human clone collection to identify and functionally validate novel targets.

“Xantos has acquired the OriGene TrueClone™ Collection and integrated its large number of otherwise inaccessible transcripts to enhance the coverage and usefulness of our infrastructure for high throughput biology and drug target discovery,” commented Ulrich Brinkmann PhD, Xantos CSO. “Results of this integration in a neurobiology target discovery project have been presented in Mol Cell Proteomics Jun 4, (2004)”. Xantos applied the OriGene clone collection very successfully for the identification of novel factors involved in adipocyte differentiation and tumor angiogenesis.

“OriGene’s mission is not only to build the most comprehensive collection of human full-length cDNAs, but also to make it a scientifically useful platform to enable systematic studies of human gene functions,” said Karl Kovacs PhD, VP of Operations at OriGene. “We are excited with this opportunity to work with Xantos to validate this mission”.

The 22,000 human full-length cDNAs in OriGene’s TrueClone™ Collection are largely derived from cDNA libraries avoiding the artifacts associated with other clone collections isolated by PCR methods. Each cDNA clone matches an annotated mRNA reference sequence from established public domains and is housed in non-proprietary expression vectors suitable for transfection and direct in vivo or in vitro expression. The comprehensive nature of the TrueClone™ Collection and the uniformity and expression-readiness of the cloning vector uniquely enables a systems biology approach to high-throughput screening and functional studies.

About Xantos Biomedicine AG - www.xantos.de

Xantos Biomedicine AG is a functional biology and drug discovery company that is focusing on the identification and validation of disease relevant human genes in the areas of cancer and metabolic diseases. Studies on disease relevant biological functions are carried out rapidly by screening for phenotypic changes caused by increase of gene function in disease relevant human cells. For this Xantos has established the proprietary high-throughput, fully automated cellular gene-transfection and assay system XantoScreen™ that is used to:

- Identify and functionally validate novel drug targets,
- Discover novel disease relevant secreted and druggable proteins,
- Conduct contract research screening projects.

XantoScreen™ enables the fully automated and standardized functional analysis of 100,000 to 300,000 genes per month in cell systems. Xantos has one of the world's largest full-length human cDNA collections (35,000 clones), several high quality cDNA libraries from various human tissues and several cell systems available for high throughput analysis.

The Company uses its technology for its own discovery program in cancer and metabolic diseases. Xantos focuses on the development of therapeutics based on secreted proteins involved in angiogenesis of cancer cells, in differentiation of fat cells and in the induction of insulin

resistance. Xantos has already identified several disease relevant new targets and proteins and is searching for collaboration partners.

Xantos is offering its technology, the human cDNA collections, libraries and functional cell assay systems on a fee-for-service basis for technology-driven interactions.

About OriGene Technologies – www.origene.com

OriGene Technologies, a molecular tool provider for system biology studies, utilizes high-throughput gene cloning and gene expression profiling to develop commercially available products for pharmaceutical, biotechnology, and academic research and discovery applications. OriGene's flagship product is the TrueClone™ Collection, a searchable gene bank of over 22,000 human full-length cDNA clones suitable for transfection and *in vivo* or direct *in vitro* expression. The TrueClone™ Collection cDNA clones are obtained directly from plasmid cDNA libraries avoiding the sequence errors introduced by other cloning methods.

For additional information regarding this announcement, please contact:

OriGene Technologies, Inc.

Rich Hamer, Ph.D.

Six Taft Court

Rockville, MD 20879

Tel: 240-620-0267

email: rhamer@origene.com

Xantos Biomedicine AG

Andrea Gnirke Ph.D.

Max-Lebsche-Platz 31

D- 81377 Muenchen

Tel: + 49 - 89 - 899 59 506

e-mail: a.gnirke@xantos.de